Details of the Drug Combinations

General Information of This Drug (ID: DME53YS)

Drug Name

Sotrastaurin acetate DME53YS

Synonyms

Sotrastaurin acetate; UNII-R1SIA15KZ1; 908351-31-5; R1SIA15KZ1; Sotrastaurin acetate [USAN]; AEB 071; Sotrastaurin acetate (USAN); SCHEMBL3846239; CHEMBL2105655; KB-74525; D09718; 3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2,5-dione acetate; 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-, acetate

Indication

Disease Entry	ICD 11	Status	REF
Renal transplantation	NE84	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Arry-162 + Sotrastaurin acetate	DC47C7H	Arry-162	Uveal Melanoma	[2]
Everolimus + Sotrastaurin acetate	DCP5CT2	Everolimus	CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma	[3]
Sotrastaurin acetate + Alpelisib	DC3OYDW	Alpelisib	Uveal Melanoma	[4]
------------------------------------------------------------------------------------

References

1	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
2	ClinicalTrials.gov (NCT01801358) A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
3	ClinicalTrials.gov (NCT01854606) Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
4	ClinicalTrials.gov (NCT02273219) Trial of AEB071 in Combination With BYL719 in Patients With Melanoma